Clarinex (Desloratadine) Side Effects
- anaphylactoid reactions
- dizziness
- drowsiness
- dysmenorrhea
- dyspepsia
- dyspnea
- edema
- elevated hepatic enzymes
- fatigue
- headache
- hyperbilirubinemia
- myalgia
- palpitations
- pharyngitis
- pruritus
- rash (unspecified)
- sinus tachycardia
- urticaria
- xerostomia
Clarinex (Desloratadine) Adverse Reactions
Due to poor penetration into the central nervous system (CNS) and a low affinity for CNS H1-receptors, CNS effects are less with desloratadine as compared to the traditional H1-antagonists, such as diphenhydramine. Desloratadine is the active metabolite of loratadine, with a relative potency of 10-20 times that of loratadine in vitro. Both loratadine and desloratadine are non-sedating; however, desloratadine does not cause QT prolongation when given in doses 4-9 times the recommended dose in adults. During pre-marketing clinical trials, adverse reactions reported in >= 2% of patients receiving desloratatadine and that were more frequently experienced as compared to placebo-treated patients include headache (14%), pharyngitis (3-5%), xerostomia (4%), fatigue (3-5%), dyspepsia (3%), somnolence (3%), dizziness (2%), dry throat (2%), flu-like symptoms (2%), myalgia (3-4%), nausea (2-5%), and dysmenorrhea (2%). The risk of drowsiness is relatively low as compared to standard, sedating antihistamines.
The following spontaneous adverse events have been reported during marketing of desloratadine: tachycardia (sinus tachycardia), palpitations and rarely hypersensitivity reactions (such as rash (unspecified), pruritus, urticaria, edema, dyspnea, and anaphylactoid reactions), and elevated hepatic enzymes including bilirubin (hyperbilirubinemia).
[ Last revised: 5/14/2004 2:28:00 PM ]
Related entries
Syndicate
|
